<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CO-BENELDOPA</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CO-BENELDOPA</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 50 mg 3&#8211;4 times a day, then (by mouth using immediate-release medicines) increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; (by mouth using immediate-release medicines) maintenance 400&#8211;800 mg daily in divided doses.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 50 mg 1&#8211;2 times a day, then (by mouth) increased in steps of 50 mg daily, dose to be increased every 3&#8211;4 days according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease (in advanced disease)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 mg 3 times a day, then increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; maintenance 400&#8211;800 mg daily in divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease (patients not taking levodopa/dopa-decarboxylase inhibitor therapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1 capsule 3 times a day; maximum 6 capsules per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease (patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1 capsule substituted for every 100 mg of levodopa and given at same dosage frequency, increased every 2&#8211;3 days according to response; average increase of 50% needed over previous levodopa dose and titration may take up to 4 weeks, supplementary dose of immediate-release Madopar may be needed with first morning dose; if response still poor to total daily dose of Madopar CR plus Madopar corresponding to 1.2 g levodopa&#8212;consider alternative therapy.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Dose is expressed as levodopa.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Caution in pregnancy&#8212;toxicity has occurred in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abnormal dreams, anorexia, anxiety, arrhythmias, chorea, confusion, dementia, depression, dizziness, drowsiness, dry mouth, dyskinesia, dystonia, euphoria, fatigue, insomnia, nausea, palpitations, postural hypotension, psychosis, syncope, taste disturbances, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Ataxia, chest pain, constipation, diarrhoea, dysphagia, flatulence, hand tremor, hoarseness, hypersalivation, hypertension, malaise, muscle cramps,, oedema, reddish discoloration of the urine and other body fluids, weakness, weight changes,
              </p>
              <p>
                <strong>rare:</strong> Abdominal pain, activation of Horner's syndrome, activation of malignant melanoma, agitation, agranulocytosis, alopecia, blepharospasm, blurred vision, bruxism, convulsions, diplopia, disorientation, duodenal ulcer, dyspepsia, dyspnoea, exanthema, flushing, gastro-intestinal bleeding, haemolytic anaemia, headache, Henoch-Sch&#246;nlein purpura, hiccups, leucopenia, neuroleptic malignant syndrome (associated with abrupt withdrawal), non-haemolytic anaemia, oculogyric crisis, paraesthesia, phlebitis, priapism, pupil dilatation, reduced mental acuity, sweating, thrombocytopenia, trismus, urinary incontinence, urinary retention,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma, suicidal ideation,
              </p>
              <p>
                <strong>notKnown:</strong> Compulsive behaviour,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>The dispersible tablets can be dispersed in water or orange squash (not orange juice) or swallowed whole.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients or carers should be given advice on how to administer co-beneldopa dispersible tablets.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Impulse control disorders</h3>
              <p>Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cushing's syndrome
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            endocrine disorders
          </li>
          <li>
            history of convulsions
          </li>
          <li>
            history of myocardial infarction with residual arrhythmia
          </li>
          <li>
            history of peptic ulcer
          </li>
          <li>
            hyperthyroidism
          </li>
          <li>
            osteomalacia
          </li>
          <li>
            phaeochromocytoma
          </li>
          <li>
            psychiatric illness (avoid if severe and discontinue if deterioration)
          </li>
          <li>
            severe cardiovascular disease
          </li>
          <li>
            severe pulmonary disease
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Co-beneldopa is a mixture of benserazide hydrochloride and levodopa in mass proportions corresponding to 1 part of benserazide and 4 parts of levodopa.</p><p>When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued 12 hours before (although interval can be shorter).</p><p>When switching from modified-release levodopa to dispersible co-beneldopa, reduce dose by approximately 30%.</p><p>When administered as an adjunct to other antiparkinsonian drugs, once therapeutic effect apparent, the other drugs may be reduced or withdrawn.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis).</p>
            </section>
      </section>




      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>False positive tests for urinary ketones have been reported.</p>
            </section>
      </section>




      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CO-BENELDOPA</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP77046"><a href="../medicinalForm/PHP77046.html" data-target="#PHP77046" data-action="load">Dispersible tablet</a></div>
            <div id="PHP77060"><a href="../medicinalForm/PHP77060.html" data-target="#PHP77060" data-action="load">Capsule</a></div>
            <div id="PHP77053"><a href="../medicinalForm/PHP77053.html" data-target="#PHP77053" data-action="load">Modified-release capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
